Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.23 USD | -8.23% | -3.04% | +74.22% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 146M |
---|---|---|---|---|---|
Net income 2024 * | -33M | Net income 2025 * | -46M | EV / Sales 2024 * | - |
Net cash position 2024 * | 94.2M | Net cash position 2025 * | 50.8M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-4.39
x | P/E ratio 2025 * |
-3.66
x | Employees | 30 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.99% |
Latest transcript on Regulus Therapeutics Inc.
1 day | -8.23% | ||
1 week | -3.04% | ||
Current month | -3.04% | ||
1 month | -12.20% | ||
3 months | +62.18% | ||
6 months | +59.29% | ||
Current year | +74.22% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Hagan
CEO | Chief Executive Officer | 55 | 16-01-03 |
Preston Klassen
PSD | President | 55 | 23-06-21 |
Crispina Calsada
DFI | Director of Finance/CFO | 54 | 19-08-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Pascale Witz
BRD | Director/Board Member | 57 | 17-05-31 |
David Baltimore
BRD | Director/Board Member | 86 | 08-12-31 |
Director/Board Member | 75 | 13-03-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-07 | 2.23 | -8.23% | 704,792 |
24-05-06 | 2.43 | -8.30% | 891,189 |
24-05-03 | 2.65 | -1.49% | 406,153 |
24-05-02 | 2.69 | +7.17% | 709,956 |
24-05-01 | 2.51 | +9.13% | 562,897 |
Delayed Quote Nasdaq, May 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+74.22% | 146M | |
+10.44% | 107B | |
+0.82% | 106B | |
+8.91% | 23.47B | |
-13.89% | 21.9B | |
-5.85% | 18.77B | |
-37.26% | 17.85B | |
-10.98% | 16.78B | |
+8.67% | 14.41B | |
+41.08% | 12.86B |
- Stock Market
- Equities
- RGLS Stock